Physician profile
Sanjeev Kumar
NPI 1932381530
$5,973.33
in general payments reported to CMS, 2019-2025
43 companies · $38.36 in 2025
The $38.36 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,514 · 2020: $671 · 2021: $435 · 2022: $325 · 2023: $1,420 · 2024: $572 · 2025: $38.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,181 · Food and Beverage: $848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,181.29 |
| Food and Beverage | $848.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,509.10 | 2019 | |
| Momentis Surgical INC. | $1,181.29 | 2023 | Anovo Surgical System |
| Abbvie INC. | $561.99 | 2019-2023 | |
| Medtronic, INC. | $349.05 | 2021-2024 | Interstim |
| Tesaro, INC. | $325.07 | 2019 | |
| Recordati_rare_diseases_inc. | $152.41 | 2024 | Sylvant |
| Ethicon US, LLC | $148.54 | 2023-2025 | Vistaseal, Stratafix |
| Glaxosmithkline, LLC. | $144.77 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $137.86 | 2020 | |
| Clovis Oncology, INC. | $129.88 | 2019-2020 | |
| Merit Medical Systems INC | $110.17 | 2024 | Bearing Nspva Embol Part |
| Amgen INC. | $110.08 | 2019-2022 | |
| Axonics, INC. | $110.07 | 2021 | |
| Merck Sharp & Dohme LLC | $106.85 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $101.53 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.